Drug intelligence / Profile preview

pembrolizumab + neratinib + paclitaxel

Development stage: Unknown
Lead developer: Merck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This triplet combination therapy consists of the PD-1 inhibitor pembrolizumab, the pan-HER tyrosine kinase inhibitor neratinib, and the microtubule-stabilizing cytotoxic agent paclitaxel. It is being investigated by Yonsei University as a second-line treatment for patients with recurrent or advanced gastric cancer who harbor somatic mutations in the HER family (EGFR, HER2, HER3, HER4) or HER2 amplification/overexpression. The regimen aims to leverage the synergistic effects of immune checkpoint blockade, targeted inhibition of the HER signaling pathway, and traditional chemotherapy to overcome resistance and improve clinical outcomes in this molecularly defined subpopulation.

Brand names: KeytrudaNerlynxTaxol
Other names: Pembrolizumab + Neratinib + Paclitaxel triplet combination

Targets

TUBB (Tubulin (alpha and beta subunits))EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on pembrolizumab + neratinib + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pembrolizumab + neratinib + paclitaxel.

Explore the full profile